AMDL Inc. in Tustin is reaping the rewards of its acquisition of Jade Pharmaceutical Inc. in China last month as it announced it had won Chinese approval to sell its antibiotic levofloxacin.

The antibiotic, part of the class of fluoroquinolones, can be used to treat pneumonia, urinary tract, and kidney and skin infections. Fluoroquinolones are one of the fastest growing markets for antibacterials.  Levofloxacin and ciprofloxacin make up 65 percent of the $3.3 billion in global sales.

AMDL will manufacture the drug at Jiangxi Jade Biochemstry Ltd. manufacturing facility in south China. For now, it will only be sold in China.

Source:佚名